Targeting serotonin 2A and adrenergic α1receptors for ocular antihypertensive agents. Discovery of 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivatives
Glaucoma affects millions of people worldwide and causes optic nerve damage and blindness. The elevation of the intraocular pressure (IOP) is the main risk factor associated with this pathology, and decreasing IOP is the key therapeutic target of current pharmacological treatments. As potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1) linked to the regulation of aqueous humour dynamics.